Q3 Earnings Forecast for QuidelOrtho Issued By William Blair

Key Points

• William Blair has downgraded its Q3 2025 earnings per share estimate for QuidelOrtho from $0.78 to $0.57, impacting the company's overall earnings forecast for FY2025.
• Analysts from various firms have reduced their price targets for QuidelOrtho, with UBS Group lowering theirs from $29.00 to $26.00 and Citigroup reducing theirs from $40.00 to $33.00.
• QuidelOrtho's stock is currently rated as "Hold" by a consensus of analysts, with a target price of $37.80 amidst a tumultuous earnings landscape.

QuidelOrtho Corporation (NASDAQ:QDEL - Free Report) - William Blair lowered their Q3 2025 earnings per share estimates for QuidelOrtho in a research report issued on Wednesday, October 8th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of $0.57 per share for the quarter, down from their previous estimate of $0.78. The consensus estimate for QuidelOrtho's current full-year earnings is $2.30 per share. William Blair also issued estimates for QuidelOrtho's FY2025 earnings at $2.18 EPS, Q1 2026 earnings at $0.76 EPS and Q3 2026 earnings at $0.68 EPS.

A number of other equities analysts have also weighed in on the company. UBS Group dropped their price objective on QuidelOrtho from $29.00 to $26.00 and set a "neutral" rating for the company in a research note on Thursday, August 7th. Citigroup reaffirmed a "neutral" rating and issued a $33.00 price objective (down previously from $40.00) on shares of QuidelOrtho in a research note on Tuesday, October 7th. Wall Street Zen lowered QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, July 26th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of QuidelOrtho in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $37.80.

QuidelOrtho Stock Performance

NASDAQ QDEL opened at $26.37 on Monday. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -4.03 and a beta of 0.27. The company has a quick ratio of 0.62, a current ratio of 1.12 and a debt-to-equity ratio of 0.74. The business has a 50-day moving average price of $27.57 and a 200-day moving average price of $28.55. QuidelOrtho has a twelve month low of $22.05 and a twelve month high of $49.45.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.11. The business had revenue of $613.90 million during the quarter, compared to analyst estimates of $612.36 million. QuidelOrtho had a positive return on equity of 5.29% and a negative net margin of 16.10%.QuidelOrtho's revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.07) earnings per share.

Institutional Investors Weigh In On QuidelOrtho

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. AQR Capital Management LLC raised its holdings in shares of QuidelOrtho by 230.3% in the first quarter. AQR Capital Management LLC now owns 2,655,576 shares of the company's stock worth $90,130,000 after buying an additional 1,851,590 shares during the period. Assenagon Asset Management S.A. boosted its position in QuidelOrtho by 201.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 941,370 shares of the company's stock valued at $27,130,000 after acquiring an additional 629,246 shares in the last quarter. Geode Capital Management LLC boosted its position in QuidelOrtho by 46.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,678,670 shares of the company's stock valued at $48,385,000 after acquiring an additional 529,770 shares in the last quarter. State Street Corp boosted its position in shares of QuidelOrtho by 23.3% in the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company's stock worth $77,841,000 after purchasing an additional 510,291 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of QuidelOrtho by 42.4% in the 1st quarter. American Century Companies Inc. now owns 1,588,645 shares of the company's stock worth $55,555,000 after purchasing an additional 473,094 shares in the last quarter. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.